Advances in Hematology / 2015 / Article / Tab 2 / Research Article
Decitabine Compared with Low-Dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed Acute Myeloid Leukemia: A Pilot Study of Safety, Efficacy, and Cost-Effectiveness Table 2 Comparison of outcomes in the study groups.
Outcome Decitabine ( ) Low-dose cytarabine ( ) Number of cycles received Median 4 4 Range (1–7) (1–14) Overall survival (in months) Median 5.5 5.5 Range (0.5–13) (0.5–17.10) Mean survival time 5.38 6.27 Testing equality of survival distribution Log-rank test, value 0.5586 Hazard ratio (95% Wald confidence interval) 0.811 (0.390–1.687) Toxicity, (%) Febrile neutropenia 5 (33.33) 5 (33.33) Anemia 8 (53.33) 7 (46.67) Neutropenia 7 (46.67) 8 (53.33) Thrombocytopenia 8 (53.33) 8 (53.33) Mucositis 4 (26.67) 4 (26.67) Hypocalcemia 3 (20.00) 2 (13.33) Hypokalemia 2 (13.33) 2 (13.33) Fatigue 4 (26.67) 5 (33.33)